ReCode Therapeutics has raised over $29 million in additional financing to advance its genetic medicines pipeline, supported by $3 million from the Cystic Fibrosis Foundation.
Amount Raised
$29 Million
Round Type
Funding Round
Menlo ParkBiotechnologyHealthcareHealth CareInvestors
Description
ReCode Therapeutics, a clinical-stage genetic medicines company, announced the close of over $29 million in additional financing. The funding will accelerate the development of inhaled mRNA therapy for cystic fibrosis. The company also reported expanded support from the Cystic Fibrosis Foundation and a new collaboration with Praxis Precision Medicines. This funding aims to enhance treatment options for genetic diseases.
Who to call at ReCode Therapeutics, and when
A new round usually means ReCode Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ReCode Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ReCode Therapeutics, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ReCode Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
ReCode Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.